STRUCTURE, LATENCY TIME AND CUMULATIVE RISK OF DEVELOPING OF THE SECOND TUMORS AT THE PATIENTS TAKING A COURSE OF TREATMENT FOR A MALIGNANT NEOPLASM IN CHILDHOOD PERIOD
https://doi.org/10.51523/2708-6011.2009-6-2-4
Abstract
The sickness rate - 59 cases of morbidity for the second tumors (1989-2007) among the sick taking a course of treatment for a malignant neoplasm in childhood period is presented, also structure of preceding pathology, latency time and cumulative risk of developing of the second tumors taking into consideration modern literary data is discussed.
About the Author
I. P. Romashevskaya
Republican Research Centre of Child Oncology and Haematology
Belarus
Belarus
References
1. The incidence of secondary leukemias / G. Leone [et al.] // Haematologica. - 1999. - Vol. 84. - P. 937-945.
2. Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation / D. Barnard [et al.] // Blood. - 2002. - Vol. 100. - P. 427-434.
3. Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia / C. H. Pui [et al.] // J. Clin. Oncol. - 2005. - Vol. 23. - P. 7936-7941.
4. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries / R. Sankila [et al.] // J. Clin. Oncol. - 1996. - Vol. 14. - P. 1442-1445.
5. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease / G. Shellong [et al.] // J Clin Oncol. - 1997. - Vol. 15. - P. 22472-22453.
6. Risk of leukemia following treatment for non Hodgkin's lymphoma / L. B. Travis [et al.] // J. Natl Cancer Inst. - 1994. - Vol. 86. - P. 1450-1457.
7. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients / J. O. Armitage [et al.] // J. Clin Oncol. - 2003. - Vol. 21. - P. 897-906.
Review
For citations:
Romashevskaya I.P. STRUCTURE, LATENCY TIME AND CUMULATIVE RISK OF DEVELOPING OF THE SECOND TUMORS AT THE PATIENTS TAKING A COURSE OF TREATMENT FOR A MALIGNANT NEOPLASM IN CHILDHOOD PERIOD. Health and Ecology Issues. 2009;(2):21-26. (In Russ.) https://doi.org/10.51523/2708-6011.2009-6-2-4
Views: 255
Email this article 